Sun Pharma gets Brazil nod for Semaglutide
Sun Pharma has received approval from the Brazilian government to sell a version of the diabetes medication Semaglutide. This approval is significant because it allows Sun Pharma to enter a new market in Brazil, where Semaglutide injectables are already a multi-million dollar industry. The approval could potentially increase competition in the market, which may lead to lower prices for consumers and benefits for Sun Pharma's bottom line.
Read the source report: The Hindu
Related coverage
- Buy P N Gadgil Jewellers; target of Rs 825: Motilal Oswal Moneycontrol · 2026-07-29
- Buy Tata Power; target of Rs 454: Motilal Oswal Moneycontrol · 2026-07-29
- Buy Varun Beverages; target of Rs 560: Motilal Oswal Moneycontrol · 2026-07-29
- Buy SAIL; target of Rs 195: Motilal Oswal Moneycontrol · 2026-07-29
- Neutral Avenue Supermarts; target of Rs 4015: Motilal Oswal Moneycontrol · 2026-07-29
- Buy Gravita India; target of Rs 2100: Motilal Oswal Moneycontrol · 2026-07-29
- Swiggy among 4 stocks showing bullish RSI upswing Economic Times · 2026-07-29
- SpaceX trades 20% below IPO price, $1.2 trillion in market cap erased Economic Times · 2026-07-29
- Lamborghini's operating profit falls as geopolitical turmoil shakes luxury car sector Reuters · 2026-07-29
- Oil Price Today (July 29): Crude oil jumps 5% as US intercepts Iranian 'surprise attack’. Big rally ahead? Economic Times · 2026-07-29
- Sensex Today | Nifty 50 | Stock Market Live Updates: Sensex rallies over 650 pts, Nifty above 24,100; IT index jumps over 2% Economic Times · 2026-07-29
- Negative Breakout: Suzlon Energy among 8 stocks that crossed below their 200 DMAs Economic Times · 2026-07-29